Patents show all

14Applications13Issued

Clinical Trials show all

5Phase 31Phase 2

SEC Filings show all

8-K9610-Q3110-K10D1S-11

Contact Information


    SEC Form D Funding Events

    DateOfferedSoldType
    2013-10-07$24,916,307$24,916,307Equity, Option to Acquire

    Key Executives

    • Martin Shkreli
      Executive Officer, Director
    • Marc Panoff
      Executive Officer
    • Horacio Plotkin
      Executive Officer
    • Stephen Aselage
      Director
    • Steve Richardson
      Director